UA86345C2 - Применение остеопротегерина для лечения и/или предотвращения фиброза - Google Patents

Применение остеопротегерина для лечения и/или предотвращения фиброза

Info

Publication number
UA86345C2
UA86345C2 UA20041008150A UA20041008150A UA86345C2 UA 86345 C2 UA86345 C2 UA 86345C2 UA 20041008150 A UA20041008150 A UA 20041008150A UA 20041008150 A UA20041008150 A UA 20041008150A UA 86345 C2 UA86345 C2 UA 86345C2
Authority
UA
Ukraine
Prior art keywords
heading
osteoprotegerin
prevention
treatment
fibrosis
Prior art date
Application number
UA20041008150A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристин Пауэ
Кристин Платер-Циберк
Original Assignee
Эплайд Рисьорч Системз Ерс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эплайд Рисьорч Системз Ерс Холдинг Н.В. filed Critical Эплайд Рисьорч Системз Ерс Холдинг Н.В.
Publication of UA86345C2 publication Critical patent/UA86345C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение относится к применению остеопротегерина для лечения и/или предотвращения фиброзных заболеваний, в частности склеродермии.
UA20041008150A 2002-04-10 2003-03-26 Применение остеопротегерина для лечения и/или предотвращения фиброза UA86345C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02100364 2002-04-10

Publications (1)

Publication Number Publication Date
UA86345C2 true UA86345C2 (ru) 2009-04-27

Family

ID=28685985

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041008150A UA86345C2 (ru) 2002-04-10 2003-03-26 Применение остеопротегерина для лечения и/или предотвращения фиброза

Country Status (18)

Country Link
US (1) US7638480B2 (ru)
EP (1) EP1515743A2 (ru)
JP (1) JP4430403B2 (ru)
KR (1) KR20040107492A (ru)
CN (1) CN1658895A (ru)
AU (1) AU2003240754B2 (ru)
BR (1) BR0309095A (ru)
CA (1) CA2480084A1 (ru)
EA (1) EA007927B1 (ru)
HR (1) HRP20040877A2 (ru)
IL (1) IL164463A (ru)
MX (1) MXPA04009884A (ru)
NO (1) NO20044658L (ru)
PL (1) PL372928A1 (ru)
RS (1) RS89204A (ru)
UA (1) UA86345C2 (ru)
WO (1) WO2003084560A2 (ru)
ZA (1) ZA200407655B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4723496B2 (ja) * 2003-09-08 2011-07-13 メルク セローノ ソシエテ アノニム 線維症疾患の治療
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
ZA200704473B (en) 2004-12-13 2008-09-25 Evogenix Ltd Osteoprotegerin variant proteins
AU2007233320B2 (en) 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
WO2009021190A2 (en) * 2007-08-08 2009-02-12 Renovar, Inc. Systems and methods for characterizing lupus erythematosus
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
WO2013169077A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 악액질 예방 또는 치료용 조성물
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
IN2014DN09951A (ru) * 2012-05-22 2015-08-14 Shire Human Genetic Therapies
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
EP2987497B1 (en) 2013-04-19 2018-12-26 Gemvax & Kael Co., Ltd. Composition for treating and preventing ischemic damage
WO2014196841A1 (en) 2013-06-07 2014-12-11 Kael-Gemvax Co., Ltd. Biological markers useful in cancer immunotherapy
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー，リミティド ホルモン分泌調節剤、及びそれを含む組成物
KR102694658B1 (ko) 2013-11-22 2024-08-14 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
EP3085380B1 (en) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US20170073391A1 (en) * 2014-03-06 2017-03-16 R-Pharm Overseas, Inc. Osteoprotegerin derived RANKL inhibitor
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物
CN105944082B (zh) * 2016-06-13 2017-08-25 浙江生创精准医疗科技有限公司 骨保护素单独或与其他细胞因子联合在治疗肝纤维化中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2864434B2 (ja) 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
US7005413B1 (en) * 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss
JP2001511010A (ja) 1997-02-06 2001-08-07 ジェネティックス・インスチチュート・インコーポレーテッド ヒトｓｄｆ−５蛋白および組成物
US6790823B1 (en) * 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
KR20010085996A (ko) * 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
YU45103A (sh) * 2000-12-06 2006-08-17 Applied Research Systems Ars Holding N.V. Upotreba sarp/1 za lečenje i prevenciju skleroderme
EP1270015A3 (en) 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease

Also Published As

Publication number Publication date
MXPA04009884A (es) 2004-12-07
JP4430403B2 (ja) 2010-03-10
HRP20040877A2 (en) 2005-02-28
EA007927B1 (ru) 2007-02-27
WO2003084560A2 (en) 2003-10-16
ZA200407655B (en) 2005-11-02
EA200401341A1 (ru) 2005-06-30
CN1658895A (zh) 2005-08-24
AU2003240754A1 (en) 2003-10-20
KR20040107492A (ko) 2004-12-20
EP1515743A2 (en) 2005-03-23
NO20044658L (no) 2004-10-28
BR0309095A (pt) 2005-02-09
PL372928A1 (en) 2005-08-08
IL164463A0 (en) 2005-12-18
US7638480B2 (en) 2009-12-29
IL164463A (en) 2011-09-27
CA2480084A1 (en) 2003-10-16
AU2003240754B2 (en) 2009-02-26
RS89204A (en) 2006-12-15
JP2005530720A (ja) 2005-10-13
WO2003084560A3 (en) 2004-02-05
US20060003928A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
HK1091209A1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
MX249034B (es) Amidinas de tiofeno novedosas, composiciones de las mismas, y metodos para tratar enfermedades y condiciones mediadas por el complemento.
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
AU3227700A (en) Skin sanitizing compositions
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
MXPA03010327A (es) USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.
WO2003002064A3 (en) Fused pyrimidine dhfr inhibitors as antibacterials
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
ZA200210316B (en) Composition and its therapeutic use.
AU2003296724A1 (en) Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders
IL164887A0 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders